STLN vs USPH
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
STLN · Starling Oncology$3.62 ▼ 45.97%
USPH · US Physical Therapy$99.49 ▲ 2.36%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- STLN +9.4%
- USPH +39.2%
Head to head
| Metric | STLN | USPH |
|---|---|---|
| Price | $3.62 | $99.49 |
| Change today | ▼ 45.97% | ▲ 2.36% |
| Market cap | $369.21M | $1.49B |
| Return, 3 months | -41.2% | +22.4% |
| Return, year to date | +1.7% | +29.9% |
| Return, 1 year | +2.1% | +38.2% |
| P/E (TTM) | – | – |
| P/B | -9.9 | 3.5 |
| P/E percentile vs own 5y | 27th | 99th |
| Dividend yield | – | 1.84% |
| Revenue growth (YoY, latest qtr) | +34.6% | +8.5% |
| Net profit growth (YoY) | +42.4% | -15.9% |
| Gross margin | 15.7% | 18.7% |
| Operating margin | -4.4% | 9.7% |
| Net margin | -5.2% | 0.3% |
| Return on equity | – | 0.6% |
| Analyst target vs. price | +176.2% | -5.8% |
| Analyst buy share | 100% | 75% |
| RSI (14) | 25 | 77 |
| 30-day volatility | 189.0% | 37.4% |
| Max drawdown, 1 year | -49.3% | -34.4% |
| Trend read | Strong downtrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- USPH is the largest of the group by market value.
- USPH has returned the most over the past year.
- STLN is growing revenue fastest.
- USPH keeps the most profit per dollar of sales.
- USPH has been the calmest stock over the last 30 days.